John C. Puente, M.D.
Cognitive Clinical Trials Research
8901 E. Pima Center Parkway, Suite 115
Scottsdale, AZ 85258

CONTACT INFORMATION:

Site Selection and Information:
Bobbie Theodore, Alliance Director
Tel. (916) 939-6696
Fax (208) 575-3169
Email: clinicaltrials@alliancesites.com

AFFILIATIONS:

Bryan LGH Medical Centers
East Campus
1600 S. 48th St.
Lincoln, NE 68506
West Campus
2300 S. 16th St.
Lincoln, NE 68502

St. Elizabeth's Regional Medical Center
555 S 70th Street
Lincoln, NE

Beatrice Community Hospital
4800 Hospital Parkway
Beatrice, NE 68310-6906

St. Mary's Hospital
1301 Grundman Blvd.
Nebraska City, NE

EDUCATION:

1996-00	M.D. University of Nebraska Medical Center, Omaha, NE
1989-92	B.S. Business Administration in Finance, Creighton University, Omaha, NE

LICENSURE:

Nebraska Medical License #22773

INTERNSHIPS AND RESIDENCIES:

2000-04 Chief Resident Neurology
University of Nebraska Medical Center, Omaha, NE

CERTIFICATION:

Board Certified Neurology, State of Nebraska
ACLS Certification
NIH Stroke Scale Certification

PROFESSIONAL EXPERIENCE:

Principal Investigator, 2018 – present
Cognitive Clinical Trials Research, Scottsdale, AZ

Neurologist, 2016- Present
Neurology Consultants of Nebraska, P.C., Omaha, NE

Company President & Neurologist, 2013-16
Multiple Sclerosis Center of Nebraska, P.C., Lincoln, NE

Neurologist, 2011-13
Neurological and Spinal Surgery, L.L.C., Lincoln, NE

Neurologist, 2004-11
Neurology Associates, P.C., Lincoln, NE

INVESTIGATOR EXPERIENCE:

ALS • Alzheimer's Disease • Multiple Sclerosis • Parkinson's Disease

INVESTIGATOR EXPERIENCE:

Alzheimer's Disease

A 12-Month, Open-Label Safety Study of XXX in Mild-to-moderate Alzheimer's Disease Patients

A Phase IIb, Randomized, Double-blind, Placebo-controlled, Multiple Dose, Biomarker and Safety Study of XXX in Mild-to-moderate Alzheimer's Disease Patients

A Phase IIa, Open-label, Multiple Dose, Safety, Pharmacokinetic and Biomarker Study of XXX in Mild-to-moderate Alzheimer's Disease Patients

INVESTIGATOR EXPERIENCE (*continued*):

A Phase III Safety and Efficacy Study of XXX in Subjects With Evidence of Early Alzheimer's Disease

ALS

A Randomized, Double-Blind, Placebo Controlled, Multicenter Study of the Safety and Efficacy of XXX in Subjects with Amyotrophic Lateral Sclerosis

Multiple Sclerosis

A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient Reported Outcomes of Oral XXX (XXX) Delayed-Release Capsules in Patients with Relapsing Forms of Multiple Sclerosis After Response to XXX

A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of XXX Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients

A Multicenter, Observational, Open-Label, Single-Arm Study of XXX in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with XXX: Stratify-2

Parkinson's Disease

Multicenter, Double-blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Effect of XXX on Motor Symptoms in Patients with Advanced Parkinson's Disease with Motor Fluctuations and Gastroparesis

Other Indications

Named Protocol XXX Patient Program with XXX